Bronchiolitis obliterans syndrome (BOS)
Clinical trials for Bronchiolitis obliterans syndrome (BOS) explained in plain language.
Never miss a new study
Get alerted when new Bronchiolitis obliterans syndrome (BOS) trials appear
Sign up with your email to follow new studies for Bronchiolitis obliterans syndrome (BOS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a biologic calm the lungs after stem cell transplant?
Disease control Recruiting nowThis phase 2 trial tests whether tezepelumab, a biologic drug that blocks a protein called TSLP, can reduce bronchial flare-ups in people who develop bronchiolitis obliterans syndrome (BOS) after an allogeneic stem cell transplant. BOS is a chronic lung condition that causes airw…
Matched conditions: BRONCHIOLITIS OBLITERANS SYNDROME (BOS)
Phase 2 • Sponsor: Hopital Foch • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug hope for lung damage after transplant
Disease control Recruiting nowThis study tests a drug called nintedanib in 20 people who developed a lung condition called bronchiolitis obliterans syndrome after a stem cell transplant. Participants take the drug daily for 12 months alongside their usual medications. The main goal is to see if the drug is sa…
Matched conditions: BRONCHIOLITIS OBLITERANS SYNDROME (BOS)
Phase 2 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC